0001555280-26-000011
SEC filingZoetis Inc. (ZTS) reported FY 2025 revenues of $9.47B, with cost of sales at $2.67B. Earnings reached $3.36B, reflecting strong operational performance in the animal health sector. Net income before allocation to noncontrolling interests was $2.67B. The company generated robust net cash from operating activities of $2.90B, supporting significant capital expenditures of $621.0M, acquisitions of $24.0M net, and substantial shareholder returns including $3.23B in treasury stock purchases and $889.0M in cash dividends. Balance sheet remains solid with total assets of $15.47B, cash and equivalents at $2.31B, and total equity of $3.33B. Long-term debt stood at $9.04B after net financing activities that included $1.85B senior notes issuance, $2.00B convertible debt proceeds, offset by $1.35B principal payments and debt-related costs. Inventories grew to $2.43B, accounts receivable at $1.59B, with property, plant, and equipment at $3.68B. Cash increased by $325.0M to end at $2.31B. Key adjustments included $487.0M depreciation and amortization, $83.0M share-based compensation, and a $3.0M loss on business disposition. No segment breakdowns disclosed. Strong cash generation funds growth and returns amid stable liquidity.
Zoetis Inc. delivered FY 2025 revenues of $9.47B and cost of sales of $2.67B, with earnings of $3.36B. Net income before allocation to noncontrolling interests was $2.67B. No prior year figures are provided in the XBRL data for direct YoY comparison. Total assets grew to $15.47B from prior periods implied by balance sheet notes, with cash and equivalents at $2.31B, matching beginning balance indicating $325.0M net increase. Equity totaled $3.33B, supported by $13.74B retained earnings offset by $10.69B treasury stock and $834.0M accumulated other comprehensive loss. Operating cash flow of $2.90B exceeded net income, driven by adjustments including $487.0M depreciation, $236.0M accounts receivable improvement, and $199.0M inventories change. Financing activities used $1.87B net, primarily $3.23B share repurchases. No segment reporting disclosed.
Revenues totaled $9.47B for the period ending 2025-12-31. No segment or geographical breakdowns are provided in the XBRL data or document content. Cost of sales was $2.67B. Other (income)/deductions-net reported $36.0M. No specific growth drivers, product lines, or regional performance details are explicitly stated. Gain (loss) on disposition of business was -$3.0M, with net cash from sale of businesses at -$4.0M. Acquisitions net of cash acquired were $24.0M, but no revenue attribution provided.
Gross profit and margins not directly disclosed. Earnings of $3.36B on $9.47B revenues imply strong profitability, with net income at $2.67B. Depreciation and amortization expense was $487.0M. Share-based compensation was $83.0M, asset impairments $47.0M, provision for inventory losses $68.0M. Deferred taxes benefited by -$52.0M. No operating expenses or margins explicitly reported. Property, plant, and equipment net was $3.68B after $2,925M accumulated depreciation.
Net cash provided by operating activities reached $2.90B, with key adjustments including $487.0M depreciation, $83.0M share-based compensation, and working capital changes like $236.0M accounts receivable and $199.0M inventories. Investing used $748.0M net, driven by $621.0M capex and $24.0M acquisitions. Financing used $1.87B net, including $3.23B treasury purchases, $889.0M dividends, offset by $3.85B debt issuances. Cash ended at $2.31B after $39.0M forex effect. Balance sheet shows $6.77B current assets, $2.23B current liabilities, $9.04B long-term debt, total liabilities $12.14B. Liquidity strong with $2.31B cash.
No management guidance, strategic priorities, or risk factors explicitly disclosed in the provided filing content. Financing activities indicate ongoing debt management and shareholder returns focus, with $2.00B convertible debt issuance and capped calls premium of $187.0M.